8-K: Cross Country Healthcare Merger End Date Extended

Cross Country Healthcare's merger agreement with Aya Holdings II Inc. has been automatically extended to December 3, 2025, as regulatory review continues.

Summary

• The End Date of the Agreement and Plan of Merger, originally dated December 3, 2024, was automatically extended from September 3, 2025, to December 3, 2025.
• The extension is in accordance with the terms of the Merger Agreement between Cross Country Healthcare, Inc., Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc.
• All other terms of the Merger Agreement remain unchanged.
• Cross Country Healthcare and Aya Holdings II Inc. have substantially complied with the U.S. Federal Trade Commission's (FTC) Second Request as of August 29, 2025.
• The merger is still expected to close in the fourth quarter of 2025, subject to customary closing conditions and receipt of certain regulatory approvals.

Sentiment

Score: 5

Explanation: The automatic extension of the merger agreement's End Date introduces a minor element of prolonged uncertainty, although the merger is still expected to close within the previously guided timeframe of Q4 2025. Substantial compliance with the FTC's Second Request is a positive step, balancing the sentiment.

Positives

• Both companies have substantially complied with the FTC's Second Request, indicating progress in the regulatory review process.
• The merger is still expected to close in the fourth quarter of 2025, maintaining the previously communicated timeline despite the End Date extension.

Negatives

• The automatic extension of the Merger Agreement's End Date suggests that regulatory approvals are taking longer than initially anticipated, prolonging the period of uncertainty.

Risks

• The timing to consummate the proposed Merger.
• The risk that a condition of closing of the proposed Merger may not be satisfied or that the closing might otherwise not occur.
• The risk that a regulatory approval required for the proposed Merger is not obtained or is obtained subject to unanticipated conditions.
• Diversion of management time on transaction-related issues.
• Disruption of management time from ongoing business operations due to the proposed Merger.
• Adverse effects on the market price of common stock due to announcements relating to the proposed Merger.
• Adverse effect on the ability to retain customers and retain and hire key personnel and maintain relationships with suppliers and customers.
• The occurrence of any event, change, or circumstance or condition that could give rise to the termination of the Merger Agreement, including in circumstances requiring a termination fee.
• The risk that competing offers will be made.
• Unexpected costs, charges, or expenses resulting from the Merger.
• Potential litigation relating to the Merger that could be instituted against the parties or their respective directors, managers, or officers.
• Worldwide economic or political changes affecting the markets served, impacting demand for services and profitability.
• Effects from global pandemics, epidemics, or other public health crises.
• Changes in marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, and customer needs.
• Disruptions in global credit and financial markets, including diminished liquidity and credit availability, changes in international trade agreements, cyber-security vulnerabilities, foreign currency volatility, swings in consumer confidence and spending, costs of providing services, retention of key employees, and outcomes of legal proceedings, claims, and investigations.

Future Outlook

The merger is expected to close in the fourth quarter of 2025, subject to the satisfaction or waiver of customary closing conditions, including receipt of certain regulatory approvals. Management's current expectations for the future of the Company are based on current expectations and assumptions relating to its business, the economy, and other future conditions.

Management Comments

• John Martins, President & Chief Executive Officer, signed the report on behalf of Cross Country Healthcare, Inc.

Industry Context

The extension of the merger agreement's end date and ongoing FTC review highlight the increasing scrutiny of consolidation within the healthcare staffing industry. This trend reflects regulatory concerns about market concentration and potential impacts on competition and labor markets for healthcare professionals, which could affect future M&A activities in the sector.

Stakeholder Impact

• Shareholders: Potential adverse effects on the market price of common stock and the amounts to be received by stockholders.
• Employees: Risk to retain and hire key personnel.
• Customers: Risk to retain customers and maintain relationships.
• Suppliers: Risk to maintain relationships with suppliers.

Next Steps

• Satisfaction or waiver of customary closing conditions for the merger.
• Receipt of certain regulatory approvals.
• Closing of the merger, expected in the fourth quarter of 2025.

Key Dates

Recommendation

While the merger with Aya Holdings II Inc. is progressing and still expected to close in Q4 2025, the automatic extension of the End Date, even if procedural, indicates ongoing regulatory hurdles. Investors should hold as the fundamental value proposition of the merger remains, but monitor for further regulatory updates or potential delays that could impact the closing timeline or terms.

Keywords

Cross Country Healthcare, Aya Healthcare, Merger, Acquisition, Healthcare Staffing, SEC Filing, 8-K, FTC Review, Regulatory Approval, Corporate Action